scholarly journals Biologics in asthma management – Are we out of breath yet?

2021 ◽  
Vol 5 (01) ◽  
pp. 96-102
Author(s):  
Nadja Struß ◽  
Jens M. Hohlfeld
Keyword(s):  
Asthma Management

Web-Based Asthma Management Coming Soon

2008 ◽  
Vol 41 (8) ◽  
pp. 23
Author(s):  
MITCHEL L. ZOLER
Keyword(s):  
Asthma Management ◽  
Web Based

Implementing a Quality Improvement Initiative for Asthma Management in a Tribal Clinic

2005 ◽  
Author(s):  
Charlanne J. FitzGerald ◽  
Beverly Hart ◽  
Adrienne Laverdure ◽  
Brian Schafer
Keyword(s):  
Quality Improvement ◽  
Asthma Management ◽  
Quality Improvement Initiative

Multisystemic Therapy Improves Asthma Management in High- Risk African American Teens

2014 ◽  
Author(s):  
S. Naar-King ◽  
D. Ellis ◽  
P.S. King ◽  
P. Lam ◽  
P. Cunningham ◽  
...  
Keyword(s):  
African American ◽  
High Risk ◽  
Asthma Management ◽  
Multisystemic Therapy

Applying personalized medicine to adult severe asthma

2021 ◽  
Vol 42 (1) ◽  
pp. e8-e16 ◽  
Author(s):  
Angelica Tiotiu
Keyword(s):  
Personalized Medicine ◽  
Severe Asthma ◽  
Negative Impact ◽  
Target Therapy ◽  
Asthma Management ◽  
Future Research ◽  
Biologic Therapies ◽  
Eosinophilic Asthma ◽  
Definition Of ◽  
Structured Approach

Background: Severe asthma is a heterogeneous disease that consists of various phenotypes driven by different pathways. Associated with significant morbidity, an important negative impact on the quality of life of patients, and increased health care costs, severe asthma represents a challenge for the clinician. With the introduction of various antibodies that target type 2 inflammation (T2) pathways, severe asthma therapy is gradually moving to a personalized medicine approach. Objective: The purpose of this review was to emphasize the important role of personalized medicine in adult severe asthma management. Methods: An extensive research was conducted in medical literature data bases by applying terms such as “severe asthma” associated with “structured approach,” “comorbidities,” “biomarkers,” “phenotypes/endotypes,” and “biologic therapies.” Results: The management of severe asthma starts with a structured approach to confirm the diagnosis, assess the adherence to medications and identify confounding factors and comorbidities. The definition of phenotypes or endotypes (phenotypes defined by mechanisms and identified through biomarkers) is an important step toward the use of personalized medicine in asthma. Severe allergic and nonallergic eosinophilic asthma are two defined T2 phenotypes for which there are efficacious targeted biologic therapies currently available. Non-T2 phenotype remains to be characterized, and less efficient target therapy exists. Conclusion: Despite important progress in applying personalized medicine to severe asthma, especially in T2 inflammatory phenotypes, future research is needed to find valid biomarkers predictive for the response to available biologic therapies to develop more effective therapies in non-T2 phenotype.

Sign in / Sign up

Export Citation Format

Share Document